

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

HS-5

RRID:CVCL_3720

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3611, RRID:CVCL_3720

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3720

Proper Citation: ATCC Cat# CRL-3611, RRID:CVCL_3720

Description: Cell line HS-5 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:7849321](#)

Comments: Population: Caucasian., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HS-5

Synonyms: HS5

Cross References: BTO:BTO_0004123, CLO:CLO_0004254, EFO:EFO_0005282, ATCC:CRL-3611, ATCC:CRL-11882, BioSample:SAMN03471343, ENCODE:ENCBS010ENC, NCBI_Iran:C626, PRIDE:PXD030239, Wikidata:Q54896276

ID: CVCL_3720

Vendor: ATCC

Catalog Number: CRL-3611

Record Creation Time: 20250130T071925+0000

Record Last Update: 20260830T001626+0000

Ratings and Alerts

No rating or validation information has been found for HS-5.

No alerts have been found for HS-5.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 339 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kato S, et al. (2026) Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. *Journal of cellular physiology*, 241(4), e70166.

He C, et al. (2026) Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia. *Advanced healthcare materials*, 15(19), e04039.

Eriksson J, et al. (2026) Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. *Cancer research*, 86(7), 1724.

Fulciniti M, et al. (2026) ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. *Blood cancer discovery*, 7(1), 129.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 45.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(21), e18975.

Gu H, et al. (2026) FAP^{hi} Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(18), e06239.

Zhang D, et al. (2025) Solute carrier-correlated gene signature in predicting the prognosis and immunity in patients with acute myeloid leukemia. *European journal of medical research*, 30(1), 1107.

Fiskus W, et al. (2025) Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. *Blood advances*, 9(21), 5598.

Oudaert I, et al. (2025) PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. *Molecular oncology*.

Sonowal H, et al. (2025) Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. *Cancer research communications*, 5(1), 74.

Yuan Y, et al. (2025) CircTADA2A inhibits cell proliferation and promotes ferroptosis by sponging miR-638 in acute myeloid leukemia. *Human cell*, 38(5), 123.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Arroyo-Berdugo Y, et al. (2025) Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia. *British journal of pharmacology*.

Zhao M, et al. (2024) RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia. *eLife*, 12.

Carmi YK, et al. (2024) Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells. *Translational oncology*, 44, 101939.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. *Research square*.

Vom Stein AF, et al. (2023) LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1. *Nature communications*, 14(1), 1330.

Pradhan L, et al. (2023) Dynamic bioinspired coculture model for probing ER+ breast cancer dormancy in the bone marrow niche. *Science advances*, 9(10), eade3186.

Cambria D, et al. (2023) IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia. *Life (Basel, Switzerland)*, 13(2).